trial

Cannabis Potency Effects on Brain White Matter in Early Phase Psychosis

NCTId NCT07001878
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 4 · Recruiting
Enrollment 24 (estimated)
Sponsored by Nova Scotia Health Authority
Primary completion 2026-08-31
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 4
Status
Recruiting
Enrollment
24 (estimated)
Study type
Interventional
Allocation
Na
Model
Single Group
Masking
None
Start
2025-03-18
Primary completion
2026-08-31
Eligibility
ALL · 18 Years · 25 Years

Interventions & indications

Drugs
Metformin

Sponsors

Nova Scotia Health AuthorityLead Sponsor
Dalhousie UniversityCollaborator

Investigators

1
Philip G Tibbo, MDPrincipal Investigator

Sites

2 total
St. John's, CanadaHalifax, Canada

Facts & assertions

4 sourced
Enrollment
24
Phase
PHASE4
Primary Completion Date
2026-08-31
Status
RECRUITING
relationships
The graph out of here
drug
Metformin
drug
lead_sponsor
Nova Scotia Health Authority
company
collaborator
Dalhousie University
company
indication
Cannabis Use
indication
Psychosis
indication
Marijuana Abuse
indication
investigator
Philip G Tibbo, MD
person